Grace Colón is a partner at New Science Ventures, where she focuses on life science investments. Grace joined New Science Ventures as a Partner in January 2014. She brings over 25 years experience in biopharma, genomics, health care and industrial biotechnology. In addition to that, she is also a CEO at BioScale.

She serves on the Board of Directors of PerceptiMed, Pyranose Biotherapeutics (which she co-founded), and InCarda Therapeutics (CEO). She is also a member of the Advisory Board of the Center for Science, Technology and Society at Santa Clara University. Previously she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) and held several senior leadership roles at Gilead Sciences (Nasdaq:GILD) and Affymetrix (Nasdaq:AFFX).

While at Affymetrix, she was also founding Chief Operating Officer of the International Genomics Consortium. Earlier in her career Grace worked at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ. Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.

Fund's investment focus: life science, biotech, pharmaceuticals, medical devices, information technology, semiconductors, photonics and advanced materials.